Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

STEALTH in transplantation tolerance.

Anne Hutchings1, William J Hubbard, Frank T Thomas

  • 1Department of Surgery, University of Alabama at Birmingham, 35294-0012, USA. hutchina@uab.edu

Immunologic Research
|October 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An estrogen (17α-ethinyl estradiol-3-sulfate) reduces mortality in a swine model of multiple injuries and hemorrhagic shock.

The journal of trauma and acute care surgery·2021
Same author

Ethinyl estradiol sulfate acts without fluid resuscitation through estrogen receptors to rapidly protect the cardiovascular system from severe hemorrhage.

The journal of trauma and acute care surgery·2020
Same author

Treatment of traumatic brain injury with 17α-ethinylestradiol-3-sulfate in a rat model.

Journal of neurosurgery·2016
Same author

The ERRor of Our Ways: Estrogen-Related Receptors are About Energy, Not Hormones, and are Potential New Targets for Trauma and Shock.

Shock (Augusta, Ga.)·2015
Same author

Salutary Effects of Estrogen Sulfate for Traumatic Brain Injury.

Journal of neurotrauma·2015
Same author

Gender differences in sepsis: cardiovascular and immunological aspects.

Virulence·2013
Same journal

Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study.

Immunologic research·2026
Same journal

Immunological spectrum in patients with thymoma: beyond good syndrome.

Immunologic research·2026
Same journal

Microbiome immune crosstalk in Sjögren's syndrome: mechanistic insights and translational perspectives.

Immunologic research·2026
Same journal

Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event.

Immunologic research·2026
Same journal

TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.

Immunologic research·2026
Same journal

Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.

Immunologic research·2026
See all related articles

Researchers developed a novel STEALTH model for transplant tolerance in nonhuman primates, achieving 62.5% kidney allograft survival at 3 years without long-term immunosuppression. This breakthrough offers hope for durable graft acceptance and improved patient outcomes.

Area of Science:

  • Transplant Immunology
  • Immunosuppression Therapy
  • Tolerance Induction

Background:

  • Current immunosuppressive drugs improve allograft acceptance but may lead to toxicity and chronic immune deficiency, compromising long-term survival.
  • The ultimate goal in transplantation is achieving donor-specific allograft acceptance without the need for continuous immunosuppression, known as tolerance.

Purpose of the Study:

  • To review the nonhuman primate STEALTH model for inducing transplant tolerance.
  • To assess the efficacy of a concise peritransplant treatment strategy for achieving long-term allograft survival.

Main Methods:

  • The STEALTH model utilizes a 2-week peritransplant treatment strategy in nonhuman primates.
  • Tolerance induction involves T cell depletion and inhibition of nuclear factor-kappaB/RelB signaling pathways.

Related Experiment Videos

Main Results:

  • The STEALTH model demonstrated an unprecedented 62.5% kidney allograft survival rate at 3 years.
  • Some primate recipients have remained healthy for over 6 years post-transplant without chronic immunosuppression.

Conclusions:

  • The STEALTH model represents a promising strategy for inducing durable transplant tolerance.
  • This approach has significant potential for future application in human transplantation, aiming to eliminate the need for long-term immunosuppressive drugs.